Portfolio Company · Operating Co.

Avadel Pharmaceuticals

Healthcare · Website

backed byVivo Capital

CurrentHealthcare

a portfolio company of

Vivo Capital

Status on record: Current

PE Firm Index

Who owns Avadel Pharmaceuticals?

Avadel Pharmaceuticals is listed as a current portfolio company of Vivo Capital on Vivo Capital's own portfolio page.

From the company's website

- Augments Alkermes’ Revenue Growth Profile and Diversifies Commercial Portfolio with New High Potential Growth Product, LUMRYZ ® (Sodium Oxybate) for Extended-Release Oral Suspension - - Expected to be Accretive in 2026 - - Positions the Combined Organization to Accelerate Innovation and

Source: investor.alkermes.com, read November 2026

Company Snapshot

Avadel Pharmaceuticals is a Healthcare company. Its owner on record, Vivo Capital, is a firm. Vivo Capital lists at least 98 companies in the index, 14 of them in Healthcare.

SectorHealthcare

Parent PE firmVivo Capital

Ownership statusCurrent

WebsiteVisit ↗

About the owner

Vivo Capital

Companies in the index: At least 98

Health-care focused investment firm.

Read the Vivo Capital profile

Questions about Avadel Pharmaceuticals

Who owns Avadel Pharmaceuticals?

Avadel Pharmaceuticals is listed as a current portfolio company of Vivo Capital on Vivo Capital's own portfolio page.

What sector is Avadel Pharmaceuticals in?

Avadel Pharmaceuticals is in Healthcare. Classified from the company's own description.

What else does Vivo Capital own in Healthcare?

Vivo Capital lists 13 other Healthcare companies in the index, including Achieve Life Sciences, Esco Lifesciences Group, Expedition Therapeutics, IO Biotech and Magnolia Medical Technologies.

What is Avadel Pharmaceuticals' website?

Avadel Pharmaceuticals' website is https://investor.alkermes.com/news-releases/news-release-details/alkermes-plc-completes-acquisition-avadel-pharmaceuticals-plc.

Sources

Vivo Capital
https://vivocapital.com/portfolio

This profile is based on publicly available information and may be incomplete or outdated. PE Firm Index is not affiliated with Avadel Pharmaceuticals and does not provide investment advice.

Other portfolio companies of Vivo Capital

6 of 97 shown

Aadi Bioscience

Ablaze Pharmaceuticals

Achieve Life Sciences

ADARx Phamaceuticals

Adaxion Therapeutics

Aerobiotix

See the full Vivo Capital portfolio.

Other Healthcare companies held by Vivo Capital

Achieve Life Sciences

Esco Lifesciences Group Expedition Therapeutics IO Biotech

Magnolia Medical Technologies

Mereo BioPharma Group

Other Healthcare portfolio companies

via Wavemaker 360 Health

3P Biopharmaceuticals

via Marlin Equity Partners

Browse PE-backed companies.

Is this your company?

Claiming is free and reviewed by hand. Correct facts and add your team.

Claim this profile Suggest a correction

Ownership

Parent PE firm

Vivo Capital

Status: Current

Check this company's website

Check this company's website now

Free, in about two minutes: the verified issues a buyer or a customer's browser would meet. Runs on GTM Brain, by DevriX.

Observational measurements of this company's public website only. Not a rating of the company, its performance, its management, or its investment merit. Not investment advice. Request a correction or removal via Submit Update.

For PE-backed companies

DevriX

DevriX runs the websites, integrations and data that bring in revenue, as one accountable engineering and operations team, through acquisitions and exit.

Where DevriX helps

Value creation through the holdRevenue, data, web and AI run as one operating cadence, tied to EBITDA.Add-ons and carve-outsConsolidate or separate platforms and unify reporting after a deal.Exit readinessFind the technology and data issues a buyer's diligence would raise, before it does.

Send DevriX a short brief

A short form on devrix.com. No call to book.

Disclosure: PE Firm Index is maintained by Mario Peshev, who founded and runs DevriX. DevriX listing

Weekly PE M&A and market research, by email

The Growth Shuttle Insider is Mario Peshev's weekly newsletter for PE owners and operators. Each issue carries the week's private equity deals from this index, market data and research, and an essay from Mario.

Free. One email a week. Unsubscribe from any issue. Your address goes to beehiiv, the service that sends the Insider.

Research

The 2027 Digital Value Creation Baseline

1,407 PE-backed companies from 179 sponsors, measured from public sources in October 2026. 15% of service and product companies have the full path from search to CRM.

Read the research

Research by Growth Shuttle and DevriX.